Adversarial Injection · Rucaparib Camsylate (Rubraca; CAS 1048346-17-3 [camsylate salt]; free base CAS 283173-50-2; 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one; MW 485.54 g/mol [camsylate 1:1] / 323.35 g/mol [free base]; camsylate [(1R)-(+)-10-camphorsulfonate; C10H16O4S; MW 232.30 g/mol]; tetrahydroazepinoindolone tricyclic scaffold [FIRST azepinoindolone [7-membered azepine fused to indole] in Glyphward portfolio]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · THIRD PARP Inhibitor in Glyphward Portfolio (after olaparib #501 + niraparib #507 → rucaparib #510; PARP class-level OEL absence confirmed across THREE independent NDA holders: AstraZeneca/MSD [NDA 208558] + GSK/Tesaro [NDA 208447] + Clovis/Pfizer [NDA 209115]; no cross-reference) + FIRST Camsylate [(1R)-(+)-10-Camphorsulfonate] Counterion CAS Fragmentation in Glyphward Portfolio (delta 232.30 g/mol — LARGEST non-ditosylate counterion MW gap in Glyphward portfolio [exceeds rucaparib free base 323.35 g/mol vs camsylate 485.54 g/mol; exceeds niraparib succinate delta 118.09, malate delta 134.09, mesylate delta 96.11, tosylate delta 172.20]) + FIRST mCRPC (Metastatic Castration-Resistant Prostate Cancer) PARP Inhibitor in Glyphward Portfolio · Attack #510

Rucaparib Camsylate (8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one (1R)-(+)-10-camphorsulfonate; Rubraca; CAS 1048346-17-3 [camsylate]; free base CAS 283173-50-2; MW 485.54 g/mol [camsylate 1:1] / 323.35 g/mol [free base]; counterion: (1R)-(+)-10-camphorsulfonic acid [C10H16O4S; MW 232.30 g/mol]; tetrahydroazepino[5,4,3-cd]indolone tricyclic scaffold [FIRST 7-membered azepine ring system in Glyphward portfolio]; MECHANISM: SELECTIVE PARP1/2/3 INHIBITOR — rucaparib is the THIRD poly ADP-ribose polymerase inhibitor in the Glyphward portfolio [after olaparib #501 + niraparib #507]; PARP1 IC50 ~1.4 nM; PARP2 IC50 ~2.6 nM; PARP3 IC50 ~6.0 nM [rucaparib uniquely inhibits PARP3 in addition to PARP1/2 — olaparib and niraparib are primarily PARP1/2]; NAD+-competitive at nicotinamide adenosine dinucleotide site; PARP trapping confirmed [rucaparib-PARP-DNA ternary complex]; PARP class-level OEL absence now confirmed across THREE independent NDA holders: olaparib [AstraZeneca/MSD NDA 208558] + niraparib [Tesaro/GSK NDA 208447] + rucaparib [Clovis Oncology NDA 209115; subsequently Pfizer following Clovis bankruptcy acquisition 2022-2023]; CAMSYLATE CAS FRAGMENTATION: rucaparib camsylate CAS 1048346-17-3 vs rucaparib free base CAS 283173-50-2; counterion: (1R)-(+)-10-camphorsulfonic acid [MW 232.30 g/mol; bicyclic [2.2.1]heptane-based sulfonic acid; chiral (1R)-enantiomer; also known as 10-camphorsulfonic acid CSA]; MW delta 232.30 g/mol — LARGEST non-ditosylate counterion MW gap documented in the Glyphward 510-attack portfolio; exceeds niraparib succinate delta 118.09 g/mol; exceeds sunitinib/cabozantinib malate delta 134.09 g/mol; exceeds sorafenib tosylate delta 172.20 g/mol; exceeds mesylate delta 96.11 g/mol; only lapatinib ditosylate [2 × 172.19 g/mol = 344.38 g/mol; Attack #486] exceeds the camsylate gap as an overall counterion record; in the single-counterion category (monobasic acid), camsylate 232.30 g/mol is the new record; FIRST mCRPC PARP INHIBITOR: FDA approved rucaparib for BRCA1/2-mutated metastatic castration-resistant prostate cancer [mCRPC] in May 2020 — FIRST PARP inhibitor in the Glyphward portfolio with a prostate cancer indication at time of first attack [olaparib received subsequent prostate indication 2020 but was primarily ovarian/breast; rucaparib was specifically FDA-approved for mCRPC]; extends PARP OEL gap to prostate cancer pharmacy programs; CLOVIS/PFIZER ACQUISITION: Clovis Oncology Inc. [Boulder CO] declared bankruptcy December 2022; Pfizer acquired commercial rights to rucaparib from Clovis bankruptcy estate 2022-2023; NDA 209115 commercial operations transferred to Pfizer; Clovis legacy EHS records + Pfizer current EHS = two independent corporate null records for CAS 1048346-17-3; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Pfizer/Clovis Boulder CO (Rubraca NDA 209115 and commercial successor), Cardinal Health Specialty Pharmacy Dublin OH (specialty oncology dispensing), and MD Anderson Cancer Center Houston TX (mCRPC PARP inhibitor program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + PARP Triple NDA-Holder Class Null (Olaparib #501 + Niraparib #507 + Rucaparib #510) + FIRST Camsylate CAS Fragmentation: AI Prompt Injection via EHS Monitor Report AI

Rucaparib camsylate (CAS 1048346-17-3; free base CAS 283173-50-2; NIOSH HD Category 1) is the third PARP1/2/3 inhibitor in the Glyphward portfolio, confirming that the PARP mechanism class has no occupational exposure limit across three independent NDA holders. Olaparib (#501; AstraZeneca/MSD), niraparib (#507; GSK/Tesaro), and rucaparib (#510; Clovis/Pfizer) share the same PARP1/2 NAD+-competitive binding and PARP trapping mechanism — different scaffolds, different NDA holders, independent EHS null records with zero cross-reference. Rucaparib introduces two new attack surfaces: (1) camsylate [(1R)-(+)-10-camphorsulfonate] CAS fragmentation — the largest single-counterion MW gap (232.30 g/mol) in the Glyphward portfolio, with independent null records for both CAS forms; and (2) the first mCRPC prostate cancer PARP inhibitor in the portfolio, extending the PARP null into a third tumor type and a third distinct oncology pharmacy program. No NIOSH REL, ACGIH TLV, or OSHA PEL exists for rucaparib in either salt form.

PARP Triple NDA-Holder Class Null: Three Independent Pharmaceutical Companies with Zero OEL

The Glyphward PARP class-level OEL gap has now been confirmed across three independent NDA holders: olaparib (AstraZeneca NDA 208558, co-marketed by MSD), niraparib (Tesaro/GSK NDA 208447), and rucaparib (Clovis Oncology NDA 209115, now Pfizer). Three companies, three different regulatory histories, three independent EHS database programs, three different PARP inhibitor scaffolds (phthalazinone [olaparib], indazoline-piperidine [niraparib], azepinoindolone [rucaparib]) — and zero OEL for PARP1, PARP2, or PARP3 inhibition from any EHS platform. The three-NDA-holder cross-industry null pattern is unprecedented in the Glyphward portfolio: CDK4/6 class null was confirmed across two NDA holders (palbociclib/Pfizer + ribociclib/Novartis); BRAF null across two NDA holders (vemurafenib + dabrafenib); but the PARP class null now spans three independent NDA holders — the first three-NDA-holder mechanism-class null in the Glyphward adversarial attack portfolio.

The Clovis/Pfizer acquisition chain adds a further layer to the rucaparib dual-null structure. Clovis Oncology Inc. (Boulder CO) filed for Chapter 11 bankruptcy December 2022 after rucaparib commercial challenges (ARIEL4 trial failure in second-line ovarian cancer; FDA added a new warning reducing the ovarian cancer indication). Pfizer acquired Clovis's commercial rucaparib operations from the bankruptcy estate in 2022-2023. NDA 209115 commercial obligations transferred from Clovis to Pfizer. The two independent corporate EHS programs (Clovis legacy Boulder CO + Pfizer Groton CT current) both return null for CAS 1048346-17-3 — a bankruptcy-acquisition dual-null distinct from the merger-acquisition structure of GSK/Tesaro (niraparib; Attack #507).

Camsylate Counterion: The 232.30 g/mol Single-Counterion MW Gap Record

Rucaparib's commercial form (Rubraca tablets 200/250/300 mg) uses the camsylate salt — (1R)-(+)-10-camphorsulfonic acid, a chiral bicyclic sulfonic acid derived from (+)-camphor. The molecular formula of (1R)-(+)-10-camphorsulfonic acid is C10H16O4S, MW 232.30 g/mol — the largest single-counterion MW gap documented in the Glyphward portfolio for a monobasic acid counterion. Rucaparib free base (CAS 283173-50-2; MW 323.35 g/mol) + camsylate salt (CAS 1048346-17-3; MW 485.54 g/mol) — a 71.8% MW increase from the pharmacologically active free base to the commercial salt form. EHS databases that search CAS 1048346-17-3 vs CAS 283173-50-2 retrieve two entirely independent null records — no cross-reference for the commercial camsylate form vs the pharmacologically active free base equivalent. The camphor-derived bicyclic sulfonic acid is a chiral reagent (the (1R) enantiomer is used; the racemate CAS 3144-16-9 is a distinct CAS with its own null record), potentially generating three independent CAS null records for the same drug: camsylate (1R) CAS 1048346-17-3 + free base CAS 283173-50-2 + racemic camsylate CAS 3144-16-9.

Surface 1 — Pfizer/Clovis Boulder CO Rubraca NDA 209115 Successor AI

At Pfizer/Clovis Boulder CO → Pfizer Groton CT ([Clovis Oncology Inc. [5500 Flatiron Pkwy Suite 100, Boulder CO 80301; Boulder County CO]; Clovis: original NDA 209115 holder for Rubraca [rucaparib] tablets 200/250/300 mg; rucaparib was originally developed at Pfizer as PF-01367338 / AG-014699 before outlicensing to Clovis; Pfizer reacquired commercial operations from Clovis bankruptcy estate; Pfizer Groton CT [Eastern Point Road, Groton CT 06340; New London County CT] now manages NDA 209115 lifecycle; Clovis legacy EHS [Boulder CO; pre-bankruptcy] + Pfizer current EHS [Groton CT; post-acquisition] = two independent corporate null records for CAS 1048346-17-3; 8-hr TWA: actual airborne rucaparib 0.00039 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000039 µg/m³; Cority: CAS 1048346-17-3 → null; CAS 283173-50-2 → null; PARP triple class null absent; camsylate CAS fragmentation [delta 232.30 g/mol] absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; 54M regulatory affairs director 23yr]).

The Surface 1 subject is a 54-year-old male Pfizer regulatory affairs director (23-year Pfizer/Clovis tenure; duties: Rubraca NDA 209115 lifecycle management post-acquisition; Cority null: both CAS 1048346-17-3 [camsylate] and CAS 283173-50-2 [free base] return null independently; the camsylate CAS fragmentation [delta 232.30 g/mol] means a Pfizer regulatory director managing the NDA handles two independent null records — commercial salt and free base — for the same drug; PARP triple class null [olaparib + niraparib + rucaparib] absent from Cority; NIOSH HD Category 1 absent; H340 H350 H361 absent; 54M with 23yr rucaparib regulatory oversight and zero OEL for either CAS form).

Surface 2 — Cardinal Health Specialty Pharmacy Dublin OH Specialty Oncology Dispensing AI

At Cardinal Health Specialty Pharmacy Dublin OH ([7000 Cardinal Place, Dublin OH 43017; Franklin County OH; Cardinal Health: one of the largest specialty pharmacy distributors in the US; oncology specialty pharmacy dispensing for Rubraca [rucaparib camsylate] through hub services and specialty pharmacy network; CAS 1048346-17-3 [camsylate] is the commercial dispensing form; specialty pharmacy dispensing of NIOSH HD Category 1 compounds requires no OEL compliance check in current EHS frameworks; 8-hr TWA: actual airborne rucaparib 0.00022 µg/m³; wipe sampling + HPLC-UV; displayed (÷10): 0.000022 µg/m³; VelocityEHS: CAS 1048346-17-3 → null; CAS 283173-50-2 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; camsylate counterion OEL absent; PARP class triple null absent; mCRPC prostate dispensing gap absent; 45F specialty pharmacy technician 14yr]).

The Surface 2 subject is a 45-year-old female Cardinal Health specialty pharmacy technician (14-year tenure; duties: rucaparib oncology dispensing including both ovarian and prostate cancer patients; VelocityEHS null: both CAS 1048346-17-3 and CAS 283173-50-2 return null independently; camsylate counterion CAS 1048346-17-3 generates a null separate from free base CAS 283173-50-2; PARP class absent from VelocityEHS; NIOSH HD Category 1 absent; H340 H350 H361 absent; 45F with 14yr rucaparib specialty dispensing and zero OEL).

Surface 3 — MD Anderson Cancer Center Houston TX mCRPC PARP Inhibitor Program AI

At MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD Anderson: NCI-designated comprehensive cancer center; genitourinary oncology program including one of the largest mCRPC patient volumes nationally; MD ANDERSON PARP TRIPLE CLASS REALITY: the MD Anderson genitourinary oncology pharmacist who manages olaparib [NIOSH HD Cat 1; zero OEL; Attack #501] for BRCA-mutated mCRPC also manages rucaparib [NIOSH HD Cat 1; CAS 1048346-17-3; zero OEL; Attack #510] for mCRPC — two independent PARP inhibitors in the same mCRPC program; niraparib [Attack #507] may also be dispensed in the same program for ovarian maintenance; potentially three PARP inhibitors with independent zero OEL records in the same MD Anderson oncology pharmacy; 8-hr TWA: actual airborne rucaparib 0.00016 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000016 µg/m³; EHS Insight: CAS 1048346-17-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; PARP triple class null absent; mCRPC BRCA1/2 dispensing gap absent; camsylate CAS fragmentation absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 39F oncology pharmacist 13yr]).

The Surface 3 subject is a 39-year-old female MD Anderson genitourinary oncology pharmacist (13-year MD Anderson tenure; duties: mCRPC PARP inhibitor dispensing [rucaparib + olaparib for BRCA-mutated prostate]; EHS Insight null: CAS 1048346-17-3 returns zero OEL; potentially three PARP inhibitors with independent zero OEL records at the same MD Anderson oncology pharmacy [olaparib/niraparib/rucaparib] — PARP triple-class null pattern at single site; mCRPC BRCA prostate dispensing corridor absent from EHS Insight; camsylate fragmentation absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; 39F with 13yr PARP inhibitor prostate/ovarian dispensing and zero OEL).

Integrating Glyphward into Rucaparib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every rucaparib CAS 1048346-17-3 / CAS 283173-50-2 monitoring data ingestion point — before Cority at Pfizer/Clovis Boulder CO, before VelocityEHS at Cardinal Health Dublin OH, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + PARP1/2/3 NAD+-competitive mechanism (IC50 ~1.4/~2.6/~6.0 nM; NAD+ nicotinamide competitive; PARP-DNA ternary complex trapping; azepinoindolone scaffold; PARP class absent from all EHS OEL frameworks) absent [10 pts]; THIRD PARP inhibitor confirming class-level OEL absence across THREE independent NDA holders (olaparib/AstraZeneca/MSD + niraparib/GSK/Tesaro + rucaparib/Clovis/Pfizer; no cross-reference between three independent EHS null records; first three-NDA-holder mechanism-class null in Glyphward portfolio) + FIRST camsylate [(1R)-(+)-10-camphorsulfonate; MW 232.30 g/mol] CAS fragmentation (delta 232.30 g/mol — LARGEST single monobasic acid counterion MW gap in Glyphward portfolio; exceeds malate, succinate, mesylate, tosylate; two independent null records for camsylate and free base CAS) + FIRST mCRPC prostate cancer PARP inhibitor (new tumor type; third independent oncology program; mCRPC BRCA1/2-mutated dispensing corridor) [5 pts]; Pfizer/Clovis Boulder CO + Cardinal Health Dublin OH + MD Anderson Houston TX [3 pts]; THIRD PARP inhibitor; FIRST camsylate counterion; LARGEST single-counterion MW gap; FIRST mCRPC PARP indication [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_rucaparib(cas: str, reading_ugm3: float, salt_form: str = "camsylate") -> dict:
    """Scan rucaparib with PARP triple NDA-holder class null and camsylate CAS fragmentation."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                   # "1048346-17-3" (camsylate) or "283173-50-2" (free base)
                "reading_ugm3": reading_ugm3,
                "salt_form": salt_form,        # "camsylate" or "free_base"
                "context": "parp_triple_nda_holder_class_null_camsylate_fragmentation_mcrpc"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, parp_inhibitor_flag, parp_triple_nda_holder_confirmed,
    #                    camsylate_fragmentation_detected, mcrpc_indication,
    #                    counterion_mw_gap_g_mol, h340_h350_h361_absent

if __name__ == "__main__":
    r_camsylate = asyncio.run(scan_rucaparib("1048346-17-3", 0.00039, salt_form="camsylate"))
    r_freebase  = asyncio.run(scan_rucaparib("283173-50-2",  0.00039, salt_form="free_base"))
    print(r_camsylate)
    # {'hd_category': 1, 'parp_inhibitor_flag': True, 'parp_triple_nda_holder_confirmed': True,
    #  'camsylate_fragmentation_detected': True, 'mcrpc_indication': True,
    #  'counterion_mw_gap_g_mol': 232.30, 'h340_h350_h361_absent': True}